TTD Drug ID: DAP000569

Drug Information
Name	Sulindac
Synonyms	Spectrum5_001024; cMAP_000021; Chibret; Copals; Z-5-Fluoro-2-methyl-1-[p-(methlsulfinyl)benzylidene]indene-3-acetic acid; cis-5-Fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; KBio2_004888; STK802068; SPBio_002206; HMS1921C11; (E)-(1)-5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; Spectrum3_001365; 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, (Z)-; Sulindacum; S2007_Selleck; C20H17FO3S; Gum copal; AC1Q6YHK; (Z)-5-Fluoro-2-methyl-1-[[4-(methyl-sulfinyl)phenyl]methylene]-1H-indene-3-acetic acid; NCGC00025268-01; KST-1B6530; AB00513800; Lopac-S-8139; Klinoril; Tocris-1707; KBioGR_001571; AR-1A9609; Prestwick_456; NCGC00015970-08; EU-0101070; Clinoril (TN); KBioSS_002322; Clinoril; UNII-M5221THD3M; {(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; Novo-Sundac; HMS2092K15; EINECS 253-819-2; KBio2_007456; Sulindac (JAN/USP/INN); Kendrick Brand of Sulindac; Sulindaco [INN-Spanish]; Sulindac [USAN:BAN:INN:JAN]; NCGC00094349-02; Apo Sulin; EINECS 250-893-8; 6301-55-9; Novopharm Brand of Sulindac; Apo-Sulin; Merck Brand of Sulindac; SPECTRUM1500556; NCGC00025268-03; D013467; C01531; Spectrum4_000876; 38194-50-2; CPD000326718; 5-Fluoro-2-methyl-1-((4-(methylsulphinyl)phenyl)methylene)-1H-indene-3-acetic acid; CID5352; IDI1_000601; Sulindaco; CID1548885; Chemia Brand of Sulindac; Sulindal; Prestwick2_000073; MK 231; (Z)-5-Fluoro-2-methyl-1-((p-(methylsulfinyl)phenyl)methylene)-1H-indene-3-acetic acid; Aflodac; SPBio_001451; KBioSS_001506; BRN 2951842; Lopac0_001070; {(1Z)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid; Aclin; CHEBI:9352; BRD-A03427350-001-01-3; Copal rosin varnish; 9000-14-0; Nu Sulindac; KBio2_001506; Prestwick1_000073; Cahill May Roberts Brand of Sulindac; 32004-68-5; 53933-60-1; MolPort-002-507-760; Novo Sundac; BSPBio_002890; KBio2_006642; HMS501O03; KBio2_002320; Alphapharm Brand of Sulindac; Sulindacum [INN-Latin]; 2-[6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; AC1LU7GY; Copal resin; DivK1c_000601; DB00605; D00120; CAS-38194-50-2; UNM-0000306136; NCGC00015970-03; MK-231; KBio2_004074; BB_SC-1128; S8139_SIAL; KBioGR_002320; Apotex Brand of Sulindac; SAM002554933; CID1548887; [(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid; Arthrocine; BPBio1_000315; Copal; EINECS 258-873-0; (Z)-5-Fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid; cis-5-Fluoro-2-methyl-1-((p-methylsulfinyl)benzylidene)indene-3-acetic acid; S8139_SIGMA; NCGC00094349-01; sulindac; Arthrobid; MLS001304027; KBio1_000601; MLS001056554; CHEMBL1376; UNII-184SNS8VUH; AC-4550; Nu Pharm Brand of Sulindac; MK231; NCGC00015970-01; LS-81610; S 8139; KBio3_002800; AC1L1K5T; AKOS004119989; HMS2089J04; SMR000326718; KBio3_002110; Nu-Pharm Brand of Sulindac; 2-[(3E)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; SMR000043852; Spectrum2_001326; HMS1568O07; Spectrum_001026; Prestwick3_000073; Sulindac sulfoxide; EINECS 232-527-9; I06-0523; NCGC00015970-02; Resin copal; Kenalin; 2-[(3Z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1-yl]acetic acid; S4429_SIAL; CCRIS 3305; {5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1h-inden-3-yl}acetic acid; AC1LU7GU; Nu-Sulindac; MolPort-003-666-287; SBB058181; NCGC00025268-02; Merck Sharp & Dohme Brand of Sulindac; BSPBio_000285; Mobilin; NINDS_000601; MLS002207124; Prestwick0_000073; BRD-A13946108-001-04-9
Trade Name	Clinoril
Company	Merck & Co
Indication	Rheumatoid arthritis			Approved    [1]
Structure	Click to save drug structure in 3D MOL format Click to save drug structure in 2D MOL format
Therapeutic Class	Anti-Inflammatory Agents
CAS Number	CAS 38194-50-2
Formular	C20H17FO3S
PubChem Compound ID	CID 1548885.
PubChem Substance ID	SID 3206270.
ChEBI	9352;
SuperDrug ATC ID	M01AB02;
SuperDrug CAS ID	038194502;
Target	Aldose reductase			Inhibitor	[2][3]
Ref 1	New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. To Reference
Ref 2	Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. To Reference
Ref 3	Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors. Invest Ophthalmol Vis Sci. 1983 Oct;24(10):1426-9. To Reference

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.